CINECA IRIS Institutional Research Information System

BUTTIGLIERO, Consuelo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.507
EU - Europa 2.721
AS - Asia 2.222
OC - Oceania 134
SA - Sud America 112
AF - Africa 75
Continente sconosciuto - Info sul continente non disponibili 10
Totale 9.781
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.334
CN - Cina 928
IT - Italia 739
SG - Singapore 398
IE - Irlanda 294
GB - Regno Unito 245
JP - Giappone 225
SE - Svezia 208
DE - Germania 188
FR - Francia 172
CA - Canada 138
IN - India 125
AU - Australia 124
UA - Ucraina 121
AT - Austria 119
ES - Italia 110
PL - Polonia 83
VN - Vietnam 80
HK - Hong Kong 79
FI - Finlandia 76
KR - Corea 76
NL - Olanda 60
TW - Taiwan 58
TR - Turchia 55
ID - Indonesia 51
BE - Belgio 49
BR - Brasile 43
GR - Grecia 35
DK - Danimarca 29
PT - Portogallo 29
IR - Iran 28
CH - Svizzera 27
MX - Messico 27
RU - Federazione Russa 26
CO - Colombia 23
IL - Israele 22
PH - Filippine 22
CL - Cile 18
RO - Romania 18
TH - Thailandia 16
LT - Lituania 13
NO - Norvegia 13
RS - Serbia 13
KE - Kenya 12
PK - Pakistan 12
ZA - Sudafrica 12
HU - Ungheria 11
EG - Egitto 10
EU - Europa 10
MY - Malesia 10
NG - Nigeria 10
NZ - Nuova Zelanda 10
CZ - Repubblica Ceca 9
GH - Ghana 9
HR - Croazia 9
MA - Marocco 9
EC - Ecuador 8
IQ - Iraq 8
LB - Libano 8
SK - Slovacchia (Repubblica Slovacca) 8
AR - Argentina 6
MO - Macao, regione amministrativa speciale della Cina 6
PE - Perù 6
SI - Slovenia 6
VE - Venezuela 5
BG - Bulgaria 4
LY - Libia 3
NI - Nicaragua 3
SN - Senegal 3
SY - Repubblica araba siriana 3
AE - Emirati Arabi Uniti 2
BJ - Benin 2
CU - Cuba 2
KW - Kuwait 2
KZ - Kazakistan 2
LU - Lussemburgo 2
LV - Lettonia 2
MT - Malta 2
NE - Niger 2
PR - Porto Rico 2
AM - Armenia 1
BO - Bolivia 1
CG - Congo 1
CY - Cipro 1
EE - Estonia 1
GE - Georgia 1
JM - Giamaica 1
JO - Giordania 1
MN - Mongolia 1
PY - Paraguay 1
SA - Arabia Saudita 1
TN - Tunisia 1
UY - Uruguay 1
ZM - Zambia 1
Totale 9.781
Salva come PNG Salva come JPEG
Città #
Chandler 448
Santa Clara 438
Singapore 313
Dublin 284
Beijing 263
Fairfield 200
Redwood City 171
Houston 170
Ashburn 161
Wilmington 133
Nyköping 132
Torino 127
Woodbridge 111
Seattle 109
Vienna 104
Turin 93
Shanghai 91
Pisa 86
Tokyo 79
Guangzhou 75
Ann Arbor 74
Columbus 71
Cambridge 67
Jacksonville 61
Villeurbanne 61
Princeton 60
Medford 59
Dong Ket 51
London 50
Warsaw 49
Dearborn 44
Jakarta 43
Nanjing 43
New York 41
Boston 36
Chengdu 36
Fremont 36
Taipei 34
Milan 31
Helsinki 28
Toronto 28
Hangzhou 27
Duncan 24
Wuhan 24
Los Angeles 23
San Diego 23
Changsha 22
Jinan 22
Hong Kong 21
Binbrook 20
Sydney 20
Athens 19
Paris 19
Brisbane 18
Chicago 18
Kalundborg 18
Madrid 17
Chennai 16
Peoria 16
Seoul 16
Boardman 15
Brussels 14
Central District 14
Istanbul 14
Philadelphia 14
Québec 14
Raritan 14
Rome 14
Shenyang 14
Bengaluru 13
Montréal 13
Santiago 13
Zhengzhou 13
Frankfurt am Main 12
Kolkata 12
Lappeenranta 12
São Paulo 12
Berlin 11
Ottawa 11
Chongqing 10
Evanston 10
Genoa 10
Kunming 10
Minneapolis 10
Munich 10
Norwalk 10
San Francisco 10
Sewell 10
Tianjin 10
Belgrade 9
Fuzhou 9
Hamburg 9
Hefei 9
Vancouver 9
Ankara 8
Buffalo 8
Derby 8
Jerusalem 8
Lanzhou 8
Montreal 8
Totale 5.416
Salva come PNG Salva come JPEG
Nome #
Addition of docetaxel to androgen deprivation therapy for patients with hormone-sensitive metastatic prostate cancer: A systematic review and meta-analysis 1.193
Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer 1.191
Hormonal treatment and quality of life of prostate cancer patients: new evidences 762
Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer 526
Molecular biomarkers to predict response to neoadjuvant chemotherapy for bladder cancer 504
Antiandrogen withdrawal syndrome (AAWS) in the treatment of patients with prostate cancer 375
The fat body mass increase after adjuvant androgen deprivation therapy is predictive of prostate cancer outcome 287
Renal cell carcinoma (RCC): Fatter is better? A review on the role of obesity in RCC 256
Therapeutic options for first-line metastatic castration-resistant prostate cancer: Suggestions for clinical practise in the CHAARTED and LATITUDE era 233
Retrospective study testing next generation sequencing of selected cancer-associated genes in resected prostate cancer 174
Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment 158
Pros-IT CNR: an Italian prostate cancer monitoring project 154
Immediate or delayed nephrectomy in patients with metastatic renal cancer who are receiving targeted agents: Is the analysis at risk for guarantee- time bias? 145
Disease-specific and general health-related quality of life in newly diagnosed prostate cancer patients: The Pros-IT CNR study 143
C28Sequencing cabazitaxel and new generation hormonal treatments in metastatic castration resistant prostate cancer patients after first line docetaxel: a retrospective analysis 142
Enzalutamide-resistant castration-resistant prostate cancer: Challenges and solutions 121
Clinical outcomes of castration-resistant prostate cancer treatments administered as third or fourth line following failure of docetaxel and other second-line treatment: Results of an Italian multicentre study 120
Immunotherapy for patients with advanced urothelial cancer: Current evidence and future perspectives 113
An exploratory analysis of the association between levels of hormones implied in steroid biosynthesis and activity of abiraterone in patients with metastatic castration-resistant prostate cancer 109
223Ra Dichloride Bone-Targeted Therapy in a Case of Metastatic Salivary Duct Carcinoma 102
Prognostic role of the duration of response to androgen deprivation therapy in patients with metastatic castration resistant prostate cancer treated with enzalutamide or abiraterone acetate 102
Androgen deprivation modulates gene expression profile along prostate cancer progression 101
Tissue Expression and Pharmacological In Vitro Analyses of mTOR and SSTR Pathways in Adrenocortical Carcinoma 96
Anti-angiogenetic therapies for central nervous system metastases from non-small cell lung cancer. 96
LATITUDE and other coordinates in quality of life of prostate cancer patients 94
Effects of Serum Testosterone Levels After 6 Months of Androgen Deprivation Therapy on the Outcome of Patients With Prostate Cancer. 93
Prognostic impact of pretreatment neutrophil-to-lymphocyte ratio in castration-resistant prostate cancer patients treated with first-line docetaxel 92
PROGNOSTIC ROLE OF SERUM TESTOSTERONE LEVELS IN PROSTATE CANCER PATIENTS DURING ANDROGEN-DEPRIVATION THERAPY 89
Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma. 84
Zoledronic Acid Dosing Interval for Metastatic Cancer 76
Antibody-Drug Conjugates in Urothelial Carcinoma: A New Therapeutic Opportunity Moves from Bench to Bedside 74
Prognostic role of vitamin d status and efficacy of vitamin D supplementation in cancer patients: a systematic review. 73
Pitfalls in the diagnosis of adrenocortical tumors: A lesson from 300 consultation cases 71
Chemotherapy-Induced Neutropenia and Outcome in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With First-Line Docetaxel 70
Abiraterone and prednisone therapy may cause severe hypoglycemia when administered to prostate cancer patients with type 2 diabetes receiving glucose-lowering agents 70
68 Ga-PSMA Uptake in Fibrous Dysplasia 70
Quality-of-Life Assessment and Reporting in Prostate Cancer: Systematic Review of Phase 3 Trials Testing Anticancer Drugs Published Between 2012 and 2018 69
How radical prostatectomy procedures have changed over the last 10 years in Italy: a comparative analysis based on more than 1500 patients participating in the MIRROR-SIU/LUNA and the Pros-IT CNR study 67
Role of radiotherapy in improving activity of immune-modulating drugs in advanced renal cancer: Biological rationale and clinical evidences 61
Are tyrosine kinase inhibitors an effective treatment in testicular metastases from kidney cancer? Case report 58
Metastatic Renal Medullary Carcinoma Treated With Immune Checkpoint Inhibitor: Case Report and Literature Review 57
On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2 56
Bipolar androgen therapy in prostate cancer: Current evidences and future perspectives 56
Prognostic factors in metastatic castration resistant prostate cancer patients treated with Radium-223: a retrospective study 55
Endocrine therapy plus zoledronic acid in premenopausal breast cancer 54
Immune-checkpoint inhibitors in previously treated patients with advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis 54
Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer 53
Treatment Landscape for Patients with Castration-Resistant Prostate Cancer: Patient Selection and Unmet Clinical Needs 51
Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with metastatic castration resistant prostate cancer treated with Abiraterone or Enzalutamide 51
Role of radium-223 discontinuation due to adverse events in castration-resistant prostate cancer patients. A retrospective monocentric analysis 51
New emerging targets in advanced urothelial carcinoma: Is it the primetime for personalized medicine? 48
Metastatic Urothelial Carcinoma: Have We Take the Road to the Personalized Medicine? 47
Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancer 46
Treatment intensification for metastatic prostate cancer: New treatment landscapes in androgen deprivation-based therapy 44
Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16) 43
Darolutamide in Metastatic Prostate Cancer 42
De novo metastatic castration sensitive prostate cancer: State of art and future perspectives 42
Interactions between androgen receptor signaling and other molecular pathways in prostate cancer progression: Current and future clinical implications 42
The prognostic value of pain in castration-sensitive prostate cancer 41
Therapeutic sequencing in advanced renal cell carcinoma: how to choose considering clinical and biological factors 40
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial 38
How Does Environmental and Occupational Exposure Contribute to Carcinogenesis in Genitourinary and Lung Cancers? 38
How to Improve the Quality of Life of Patients with Prostate Cancer Treated with Hormone Therapy? 37
New Perspectives in the Medical Treatment of Non-Muscle-Invasive Bladder Cancer: Immune Checkpoint Inhibitors and Beyond 36
First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin 36
Pathological and molecular features of adrenocortical carcinoma: an update 35
Prognostic role of early PSa drop in castration resistant prostate cancer patients treated with abiraterone acetate or enzalutamide 33
Adverse event assessment in prostate cancer patients receiving androgen deprivation therapy: are we doing enough? 32
Evaluation of cognitive function in trials testing new-generation hormonal therapy in patients with prostate cancer: A systematic review 30
Antiandrogens as Therapies for COVID-19: A Systematic Review 28
Prognostic Role of Serum Parathyroid Hormone Levels in Advanced Prostate Cancer Patients Undergoing Zoledronic Acid Administration 28
Navigating the ICI Combination Treatment Journey: Patterns of Response and Progression to First-Line ICI-Based Combination Treatment in Metastatic Renal Cell Carcinoma 27
Synchronous or metachronous presentation of pancreatic neuroendocrine tumor versus secondary lesion to pancreas in patients affected by renal cell carcinoma. Systematic review 26
Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort 26
Non-invasive detection of neuroendocrine prostate cancer through targeted cell-free DNA methylation 25
Addition of New Androgen Receptor Pathway Inhibitors to Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Metanalysis 25
Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study 25
Synthetic Lethality by Co-Inhibition of Androgen Receptor and Polyadenosine Diphosphate-Ribose in Metastatic Prostate Cancer 23
Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21) 21
Maintenance versus discontinuation of androgen deprivation therapy during continuous or intermittent docetaxel administration in castration-resistant prostate cancer patients: A multicentre, randomised Phase III study by the Piemonte Oncology Network 21
TEAM Study: Upfront Docetaxel Treatment in Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Real-World, Multicenter, Retrospective Analysis 19
Treatment options in first-line metastatic renal carcinoma: A meta-analysis of 2556 patients treated with immune checkpoint inhibitors-based combinations in randomised controlled trials 18
Avelumab Plus Intermittent Axitinib in Previously Untreated Patients with Metastatic Renal Cell Carcinoma. The Tide-A Phase 2 Study 17
Impact of Neuroendocrine Differentiation (NED) on Enzalutamide and Abiraterone Efficacy in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Retrospective Analysis 17
Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses 16
Safety profile of darolutamide versus placebo: a systematic review and meta-analysis 15
Hormonal Agents in Localized and Advanced Prostate Cancer: Current Use and Future Perspectives 13
Totale 10.092
Salva come PNG Salva come JPEG
Categoria #
all - tutte 28.933
article - articoli 0
book - libri 0
conference - conferenze 309
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 29.242
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020853 0 0 0 0 0 140 132 111 177 112 90 91
2020/20211.096 57 99 84 101 117 92 98 57 79 84 74 154
2021/20221.118 78 79 67 86 63 41 62 53 69 93 288 139
2022/20231.929 129 192 73 148 184 401 122 152 213 89 132 94
2023/20241.164 116 159 71 111 81 141 86 75 21 81 101 121
2024/20251.355 76 191 127 187 564 210 0 0 0 0 0 0
Totale 10.092